Login to Your Account



Orion, Bayer target prostate cancer with new phase III

By Michael Fitzhugh
Staff Writer

Tuesday, September 16, 2014
Orion Corp. and Bayer Healthcare AG, part of Bayer AG, have begun to enroll patients in a phase III trial of ODM-201, an oral androgen receptor (AR) inhibitor the companies are co-developing to treat castration-resistant prostate cancer (CPRC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription